BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

10:11 AM
Jan 12, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AmpliPhi reports data from expanded access program for bacteriophages

AmpliPhi Biosciences Corp. (NYSE-M:APHB) reported data from seven patients with serious, life-threatening infections who did not respond to antibiotics from an expanded access program showing that AB-SA01 or AB-PA01 (Biophage-PR, AmpliPhage-001) in combination with best available antibiotic therapy led to...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >